Common Polymorphisms of the Growth Hormone (GH) Receptor Do Not Correlate with the Growth Response to Exogenous Recombinant Human GH in GH-Deficient Children
A. Pilotta,
P. Mella,
M. Filisetti,
B. Felappi,
E. Prandi,
G. Parrinello,
L. D. Notarangelo and
F. Buzi
Department of Pediatrics (A.P., M.F., B.F., E.P., L.D.N., F.B.), Institute of Molecular Medicine A. Nocivelli (P.M.), and Section of Medical Statistics (G.P.), University of Brescia, 25123 Brescia, Italy
Address all correspondence and requests for reprints to: Dr. F. Buzi, Clinica Pediatrica dellUniversità di Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy. E-mail: fbuzi{at}med.unibs.it.
Context: GH acts through the GH receptor (GHR), whose polymorphismsmight affect the growth response to recombinant human GH (rhGH).
Objective: The objective of this study was to investigate possibleinfluences of GHR polymorphisms on the growth response to rhGHin GH-deficient (GHD) children.
Design: This was a 2-yr study (first year, spontaneous growth;second year, growth during rhGH treatment).
Setting: This study was performed at a referral center.
Patients: Fifty-four prepubertal GHD children (11 females; meanage, 7.8 yr; SD, 3.96) were studied.
Intervention: Patients were treated with rhGH (0.2 mg/kg·wk)for at least 1 yr after diagnosis. Growth velocity (GV) wasmeasured 1 yr before treatment and during the first treatmentyear. GHR exons were amplified by PCR using pairs of intronicprimers. The presence of single or multiple mismatches in thePCR products was revealed by denaturing high-pressure liquidchromatography. For exons in which mismatches were found bydenaturing high-pressure liquid chromatography, direct sequencingwas performed by automatic sequencer.
Main Outcome Measures: Before the start of treatment, the meanheight (Ht) SD score was 1.93 (SD, 0.70), and the meanGV SD score was 1.49 (SD, 1.26).
Results: The posttreatment (first 12 months) mean GV SD scorewas 3.55 (SD, 3.27). Molecular analysis revealed a high frequencyof GHR polymorphisms; in particular: exon 3 deletion (Del 3)in 26 subjects (48%), polymorphism 504 A>G at codon 168 ofexon 6 in 44 (82%), and polymorphism 1576 A>C at codon 526of exon 10 in 35 (65%). In most patients, these different polymorphismsrecurred in association. We found no significant differencesin GV between the groups of subjects defined by the polymorphicgenotypes.
Conclusion: The most common GHR polymorphisms, alone or in association,do not appear to affect the growth response to rhGH in GHD children.
This article has been cited by other articles:
O R Adetunji, I A MacFarlane, M Javadpour, A Alfirevic, M Pirmohamed, and J C Blair The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy
Eur. J. Endocrinol.,
October 1, 2009;
161(4):
541 - 546.
[Abstract][Full Text][PDF]
M. J. E. Wassenaar, O. M. Dekkers, A. M. Pereira, J. M. Wit, J. W. Smit, N. R. Biermasz, and J. A. Romijn Impact of the Exon 3-Deleted Growth Hormone (GH) Receptor Polymorphism on Baseline Height and the Growth Response to Recombinant Human GH Therapy in GH-Deficient (GHD) and Non-GHD Children with Short Stature: A Systematic Review and Meta-Analysis
J. Clin. Endocrinol. Metab.,
October 1, 2009;
94(10):
3721 - 3730.
[Abstract][Full Text][PDF]
P. Kamenicky, C. Dos Santos, C. Espinosa, S. Salenave, F. Galland, Y. Le Bouc, P. Maison, P. Bougneres, and P. Chanson D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly
Eur. J. Endocrinol.,
August 1, 2009;
161(2):
231 - 235.
[Abstract][Full Text][PDF]
E. J. L. Barbosa, J. Palming, C. A. M. Glad, H. Filipsson, J. Koranyi, B.-A. Bengtsson, L. M. S. Carlsson, C. L. Boguszewski, and G. Johannsson Influence of the Exon 3-Deleted/Full-Length Growth Hormone (GH) Receptor Polymorphism on the Response to GH Replacement Therapy in Adults with Severe GH Deficiency
J. Clin. Endocrinol. Metab.,
February 1, 2009;
94(2):
639 - 644.
[Abstract][Full Text][PDF]
G. Kenth, J. A M. Mergelas, and C. G. Goodyer Developmental changes in the human GH receptor and its signal transduction pathways
J. Endocrinol.,
July 1, 2008;
198(1):
71 - 82.
[Abstract][Full Text][PDF]
A. A. van der Klaauw, T. van der Straaten, R. Baak-Pablo, N. R. Biermasz, H.-J. Guchelaar, A. M. Pereira, J. W. A. Smit, and J. A. Romijn Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults
J. Clin. Endocrinol. Metab.,
July 1, 2008;
93(7):
2828 - 2834.
[Abstract][Full Text][PDF]
B. Raz, M. Janner, V. Petkovic, D. Lochmatter, A. Eble, M. T. Dattani, P. C. Hindmarsh, C. E. Fluck, and P. E. Mullis Influence of Growth Hormone (GH) Receptor Deletion of Exon 3 and Full-Length Isoforms on GH Response and Final Height in Patients with Severe GH Deficiency
J. Clin. Endocrinol. Metab.,
March 1, 2008;
93(3):
974 - 980.
[Abstract][Full Text][PDF]
A. Carrascosa, L. Audi, M. Fernandez-Cancio, C. Esteban, P. Andaluz, E. Vilaro, M. Clemente, D. Yeste, M. A. Albisu, and M. Gussinye The Exon 3-Deleted/Full-Length Growth Hormone Receptor Polymorphism Did Not Influence Growth Response to Growth Hormone Therapy over Two Years in Prepubertal Short Children Born at Term with Adequate Weight and Length for Gestational Age
J. Clin. Endocrinol. Metab.,
March 1, 2008;
93(3):
764 - 770.
[Abstract][Full Text][PDF]
A. Carrascosa, L. Audi, C. Esteban, M. Fernandez-Cancio, P. Andaluz, M. Gussinye, M. Clemente, D. Yeste, and M. A. Albisu Growth Hormone (GH) Dose, But Not Exon 3-Deleted/Full-Length GH Receptor Polymorphism Genotypes, Influences Growth Response to Two-Year GH Therapy in Short Small-for-Gestational-Age Children
J. Clin. Endocrinol. Metab.,
January 1, 2008;
93(1):
147 - 153.
[Abstract][Full Text][PDF]
F. Schreiner, S. Stutte, P. Bartmann, B. Gohlke, and J. Woelfle Association of the Growth Hormone Receptor d3-Variant and Catch-up Growth of Preterm Infants with Birth Weight of Less Than 1500 Grams
J. Clin. Endocrinol. Metab.,
November 1, 2007;
92(11):
4489 - 4493.
[Abstract][Full Text][PDF]
R. G Rosenfeld Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature
Eur. J. Endocrinol.,
August 1, 2007;
157(suppl_1):
S27 - S31.
[Abstract][Full Text][PDF]
R. B. Jensen, S. Vielwerth, T. Larsen, G. Greisen, H. Leffers, and A. Juul The Presence of the d3-Growth Hormone Receptor Polymorphism Is Negatively Associated with Fetal Growth but Positively Associated with Postnatal Growth in Healthy Subjects
J. Clin. Endocrinol. Metab.,
July 1, 2007;
92(7):
2758 - 2763.
[Abstract][Full Text][PDF]
G. Kenth, Z. Shao, D. E. C. Cole, and C. G. Goodyer Relationship of the Human Growth Hormone Receptor Exon 3 Genotype with Final Adult Height and Bone Mineral Density
J. Clin. Endocrinol. Metab.,
February 1, 2007;
92(2):
725 - 728.
[Abstract][Full Text][PDF]
L. Audi, C. Esteban, A. Carrascosa, R. Espadero, A. Perez-Arroyo, R. Arjona, M. Clemente, H. Wollmann, L. Fryklund, L. A. Parodi, et al. Exon 3-Deleted/Full-Length Growth Hormone Receptor Polymorphism Genotype Frequencies in Spanish Short Small-for-Gestational-Age (SGA) Children and Adolescents (n = 247) and in an Adult Control Population (n = 289) Show Increased fl/fl in Short SGA
J. Clin. Endocrinol. Metab.,
December 1, 2006;
91(12):
5038 - 5043.
[Abstract][Full Text][PDF]
W. F. Blum, K. Machinis, E. P. Shavrikova, A. Keller, H. Stobbe, R. W. Pfaeffle, and S. Amselem The Growth Response to Growth Hormone (GH) Treatment in Children with Isolated GH Deficiency Is Independent of the Presence of the Exon 3-Minus Isoform of the GH Receptor
J. Clin. Endocrinol. Metab.,
October 1, 2006;
91(10):
4171 - 4174.
[Abstract][Full Text][PDF]
A. Carrascosa, C. Esteban, R. Espadero, M. Fernandez-Cancio, P. Andaluz, M. Clemente, L. Audi, H. Wollmann, L. Fryklund, L. Parodi, et al. The d3/fl-Growth Hormone (GH) Receptor Polymorphism Does Not Influence the Effect of GH Treatment (66 {micro}g/kg per Day) or the Spontaneous Growth in Short Non-GH-Deficient Small-for-Gestational-Age Children: Results from a Two-Year Controlled Prospective Study in 170 Spanish Patients
J. Clin. Endocrinol. Metab.,
September 1, 2006;
91(9):
3281 - 3286.
[Abstract][Full Text][PDF]